Table 1. The clinical data of patients with AML based on the immune scores and stromal scores.
| Characteristic | Immune score(range) | Stromal score(range) | Cases |
| Age | |||
| <60 | (1368.53-3758.87) | (-1888.81--202.78) | 90 |
| ≥60 | (1329.53-3971.97) | (-1753.86-435.75) | 83 |
| Gender | |||
| Female | (1329.53-3971.97) | (-1888.81-435.75) | 80 |
| Male | (1475.85-3758.87) | (-1660.43- -207.13) | 93 |
| Neoadjuvant treatment | |||
| Yes | (1329.53-3971.97) | (-1888.81-435.75) | 45 |
| No | (1475.85-3758.87) | (-1735.4- -207.13) | 128 |
| FAB subtype | |||
| M0 | (1606.38-3481.5) | (-1534.51- -705.43) | 16 |
| M1 | (1329.53-3432.53) | (-1888.81- -297.73) | 42 |
| M2 | (1637.44- 3352.15) | (-1735.4- -235.75) | 39 |
| M3 | (1475.85-2707.91) | (-1571.73-1734.11) | 16 |
| M4 | (1823.93-3758.87) | (-1249.43- -352.55) | 35 |
| M5 | (2388.6-3971.97) | (-1693.75-435.75) | 18 |
| M6 | (2698.17-3116.63) | (-754.82- -494.19) | 2 |
| M7 | (1970.08-2489.15) | (-1094.44- -207.18) | 3 |
| Unkown | (1625.8-2150.49) | (-1462.53- -1398.47) | 2 |
| Cytogenetics_risk_category | |||
| Favorable | (1475.85-3758.87) | (-1571.73- -425.53) | 32 |
| Normal | (1329.53-3971.97) | (-1753.86-435.75) | 103 |
| Poor | (1625.8-3481.5) | (-1888.81- -235.75) | 36 |
| NA | (1839.34-2510.82) | (-1735.4- -1470.38) | 2 |
| Survival status | |||
| Alive | (1329.53-3758.87) | (-1888.81- -202.78) | 70 |
| Dead | (1579.75-3971.97) | (-1735.4- 435.75) | 103 |
*AML: Acute Myeloid Leukaemia; FAB: French-American-British.